Effects of Rituximab on JAK-STAT and NF-kappa B signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia

Dalmlzrak, Aysegul; Gunel, NUR; Kaymaz, BURÇİN; Şahin, FAHRİ; Saydam, GÜRAY; Kosova, BUKET

doi:10.1515/tjb-2018-0321

Effects of Rituximab on JAK-STAT and NF-kappa B signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia

Atıf İçin Kopyala

Dalmlzrak A., Gunel N. , Kaymaz B. , Şahin F. , Saydam G. , Kosova B.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.44, no.1, ss.499-509, 2019 (SCI İndekslerine Giren Dergi)

Cilt numarası: 44 Konu: 4
Basım Tarihi: 2019
Doi Numarası: 10.1515/tjb-2018-0321
Dergi Adı: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
Sayfa Sayıları: ss.499-509

Özet

Objectives: Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-kappa B signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) and B-CLL.